VRAX (Virax Biolabs Group) Asset Turnover: 0.00 (As of Sep. 2025)


VRAX Virax Biolabs Group Ltd VRAX
37 GF Score
Price $3.09
GF Value $1.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Virax Biolabs Group Asset Turnover?

Virax Biolabs Group VRAX -0.64% 37 Asset Turnover is 0.00 as of Sep. 2025. GuruFocus rates VRAX with a GF Score™ of 37/100 and a GF Value™ of $1.15 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Virax Biolabs Group's Revenue for the six months ended in Sep. 2025 was $0.00 Mil. Virax Biolabs Group's Total Assets for the quarter that ended in Sep. 2025 was $6.07 Mil. Therefore, Virax Biolabs Group's Asset Turnover for the quarter that ended in Sep. 2025 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Virax Biolabs Group's annualized ROE % for the quarter that ended in Sep. 2025 was -84.99%. It is also linked to ROA % through Du Pont Formula. Virax Biolabs Group's annualized ROA % for the quarter that ended in Sep. 2025 was -77.05%.

Virax Biolabs Group  (NAS:VRAX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Virax Biolabs Group's annulized ROE % for the quarter that ended in Sep. 2025 is

ROE %**(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=-4.678/5.504
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.678 / 0.004)*(0.004 / 6.071)*(6.071/ 5.504)
=Net Margin %*Asset Turnover*Equity Multiplier
=-116950 %*0.0007*1.103
=ROA %*Equity Multiplier
=-77.05 %*1.103
=-84.99 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Virax Biolabs Group's annulized ROA % for the quarter that ended in Sep. 2025 is

ROA %(Q: Sep. 2025 )
=Net Income/Total Assets
=-4.678/6.071
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.678 / 0.004)*(0.004 / 6.071)
=Net Margin %*Asset Turnover
=-116950 %*0.0007
=-77.05 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Virax Biolabs Group Asset Turnover Related Terms

Virax Biolabs Group Asset Turnover Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Asset Turnover Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Asset Turnover
Get a 7-Day Free Trial 3.94 0.00 0.00 0.02 0.00

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 0.00 0.00

VRAX vs BBLG, PKTX, OGEN: Asset Turnover Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Asset Turnover falls into.


VRAX
37GF Score
Virax Biolabs Group Ltd VRAX
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Virax Biolabs Group's Asset Turnover for the fiscal year that ended in Mar. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2025 )/( (Total Assets (A: Mar. 2024 )+Total Assets (A: Mar. 2025 ))/ count )
=0.006/( (5.484+6.427)/ 2 )
=0.006/5.9555
=0.00

Virax Biolabs Group's Asset Turnover for the quarter that ended in Sep. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=0.002/( (6.427+5.715)/ 2 )
=0.002/6.071
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Virax Biolabs Group (VRAX) has a Asset Turnover of 0.00 as of Sep. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Asset Turnover too high?
Virax Biolabs Group's current Asset Turnover is 0.00. Overall, Virax Biolabs Group has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Asset Turnover compare to BBLG and PKTX?
Virax Biolabs Group's Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.15, compared to a current price of $3.09 — trading 168.7% above its estimated fair value. The current Asset Turnover is 0.00. Virax Biolabs Group's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Asset Turnover is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued. The current stock price of $3.09 is trading 168.7% above its estimated GF Value™ of $1.15. GuruFocus considers Virax Biolabs Group to be Significantly Overvalued.

Key valuation signals for VRAX:

  • Asset Turnover: 0.00
  • GF Value™: $1.15 vs. price of $3.09 (168.7% above fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
37GF Score

Get the complete analysis for VRAX

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price
$1.15
GF Value